Matthew Ghermezi

Oncotherapeutics (United States) — United States

Medicine · Health Sciences

6h-index171citations21works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(15), Protein Degradation and Inhibitors(6), Myeloproliferative Neoplasms: Diagnosis and Treatment(4), Lymphoma Diagnosis and Treatment(3), Research on Leishmaniasis Studies(3)

Publications21 total

Data from A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma
2023Open Access
Supplementary Data from A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma
2023Open Access
Supplementary Data from A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma
2023Open Access
Data from A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma
2023Open Access
A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients
Hematological Oncology·2022· 9 cited
Serum B-Cell maturation antigen is an independent prognostic marker in previously untreated chronic lymphocytic leukemia
Experimental Hematology·2022· 4 cited
A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma
Leukemia & lymphoma/Leukemia and lymphoma·2021· 5 cited
A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma
Clinical Cancer Research·2020· 35 cited
A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM)
Clinical Lymphoma Myeloma & Leukemia·2019
A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination with Pomalidomide, Carfilzomib and Dexamethasone for High Risk Relapsed/ Refractory Multiple Myeloma Patients
Clinical Lymphoma Myeloma & Leukemia·2019· 2 cited
The role of JAK inhibitors in multiple myeloma.
PubMed·2019· 15 cited
Plasma B-Cell Maturation Antigen Levels are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia
Targeted Oncology·2019· 19 cited
A phase I trial of ruxolitinib, lenalidomide, and methylprednisolone for patients with relapsed/refractory multiple myeloma (MM).
Journal of Clinical Oncology·2019· 1 cited
Serum B-cell maturation antigen as a prognostic marker for untreated chronic lymphocytic leukemia.
Journal of Clinical Oncology·2019· 2 cited
Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells
Leukemia Research·2019· 69 cited
Issue Information
European Journal Of Haematology·2018Open Access
Changes in Serum B-Cell Maturation Antigen Levels Are a Rapid and Reliable Indicator of Treatment Efficacy for Patients with Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2017· 7 cited
Changes in Serum B-Cell Maturation Antigen Levels Are a More Rapid Indicator of Therapeutic Response or Disease Progression for Patients with Multiple Myeloma
Blood·2016· 1 cited
Serum CD147 Levels Are Increased in Multiple Myeloma Patients and Elevated Levels Are Associated with Refractory Disease and Shortened Progression Free Survival
Blood·2016· 2 cited
Serum B-Cell Maturation Antigen is a Novel Prognostic Indicator for Multiple Myeloma Patients and Correlates with Clinical Status and Survival
Research·2015
page 1 of 2Next →

Frequent Co-authors

James R. Berenson(19), Tanya M. Spektor(17), Regina A. Swift(14), Benjamin Eades(11), Daisy Martinez(10), Gary K. Schwartz(10), Shahrooz Eshaghian(10), Robert Vescio(10), Jennifer To(8), Carley Turner(8), Armando Sánchez(7), Laura Stampleman(7), Eric Sanchez(6), Camilia Soof(6), Kyle A. Udd(6), Stephen Lim(6), Mingjie Li(4), Sean Bujarski(4), Robert A. Moss(4), Robert A. Moss(4)